13414-55-6Relevant academic research and scientific papers
Potent inhibitors of Acyl-CoA:cholesterol acyltransferase. 2. Structure- activity relationships of novel N-(2,2-dimethyl-2,3-dihydrobenzofuran-7- yl)amides
Kataoka,Shiota,Takeyasu,Minoshima,Watanabe,Tanaka,Mochizuki,Taneda,Ota,Tanabe,Yamaguchi
, p. 1262 - 1270 (1996)
Novel N-(2,2-dimethyl-2,3-dihydrobenzofuran-7-yl)amide derivatives 1 were synthesized and tested for their ability to inhibit rabbit small intestinal ACAT (acyl-CoA:cholesterol acyltransferase) and lower serum total cholesterol in cholesterol-fed rats. Among the synthesized compounds, N-(2,2,4,6- tetramethyl-2,3-dihydrobenzofuran-7-yl)amide derivatives showed potent ACAT inhibitory activity. The synthesis and structure-activity relationships of these compounds are described. A methyl group at position 6 of the 2,3- dihydrobenzofuran moiety was important for potent ACAT inhibitory activity. In the series of N-(2,2,4,6-tetramethyl-2,3-dihydrobenzofuran-7-yl)amides, lipophilicity of the acyl moiety was necessary for the potent ACAT inhibitory activity. The highly lipophilic acid amides N-(2,2,4,6-tetramethyl-2,3- dihydrobenzofuran-7-yl)-2,2-dimethyldodecanamide (10) and 6-(4- chlorophenoxy)-N-(2,2,4,6-tetramethyl-2,3-dihydrobenzofuran-7-yl)-2,2- dimethyloctanamide (50) showed potent activity. Introduction of a dimethylamino group at position 5 of the 2,3-dihydrobenzofuran moiety resulted in highly potent activity. The most potent compound, N-[5- (dimethylamino)-2,2,4,6-tetramethyl-2,3-dihydrobenzofuran-7-yl]-2,2- dimethyldodecanamide (13, TEI-6620), showed highly potent ACAT inhibitory activity (rabbit small intestine IC50 = 0.020 μM, rabbit liver IC50 = 0.009 μM), foam cell formation inhibitory activity (rat peritoneal macrophage IC50 = 0.030 μM), extremely potent serum cholesterol-lowering activity in cholesterol-fed rats (71% at a dose of 0.3 mg/kg/day po), and good bioavailability in fed dogs (C(max) = 2.68 μg/mL at 1 h, 10 mg/kg po).
